What Is Platelet-Derived Growth Factor Receptor? What Research Reports

Plain definition

Platelet-derived growth factor receptor (PDGFR) is a cell-surface receptor tyrosine kinase: a protein that spans the outer membrane of a cell, binds a specific growth-factor protein on the outside, and switches on enzymatic signalling on the inside. Its natural binding partners are the platelet-derived growth factor (PDGF) polypeptides, which circulate and act locally as dimers. Two closely related receptor genes exist in humans and other mammals, usually written PDGFRα (PDGFRA) and PDGFRβ (PDGFRB). When a PDGF dimer bridges two receptor molecules, the pair phosphorylates itself and then other intracellular proteins, launching cascades that influence whether a cell divides, moves, survives or changes its identity. In short, PDGFR is the receiving end of a growth-factor conversation rather than a peptide that is administered.

What class of molecule it is, and where it comes from

PDGFRα and PDGFRβ belong to the same structural family as the receptors for stem cell factor (CD117/KIT), colony-stimulating factor 1 and FLT3. Each receptor has an extracellular region built from immunoglobulin-like domains, a single membrane-spanning segment, and an intracellular kinase domain. The ligands were originally identified in platelets — hence the name — but PDGF chains are also produced by endothelial cells, macrophages, epithelial cells and tumour cells, so the system operates throughout tissues and not only at sites of clotting.

Receptor expression is characteristically found on mesenchymal and perivascular cells. PDGFRβ is a standard marker of pericytes, the cells wrapped around small vessels, while PDGFRα labels many fibroblast populations, oligodendrocyte precursor cells and certain progenitors. Immunohistochemical work in the neonatal rat brain reported that NG2 and PDGFRα were expressed in the developing brain with patterns consistent with oligodendrocyte-lineage progenitors (PMID 29239330). In skin, a dermatology study examined CD117 and PDGFRα expression in patients with alopecia areata alongside controls (PMID 32461384).

How the term is used in peptide and growth-factor research

Readers encounter "platelet-derived growth factor receptor" in several distinct senses, and the distinctions matter when interpreting a paper:

• As a signalling pathway. Authors write "PDGFR signalling" to mean the whole ligand–receptor–kinase axis, usually manipulated by genetic deletion, mutation or kinase inhibition rather than by giving a peptide.
• As a cell-identity marker. PDGFRα and PDGFRβ antibodies are used to label fibroblasts, pericytes and progenitor cells in tissue sections and flow cytometry.
• As a molecular target. Some studies test whether blocking, deleting or homing to the receptor changes a disease process in animals or cultured cells.
• As a ligand-related term. PDGF itself is a growth-factor polypeptide; the receptor is the protein it binds. Sources that blur "PDGF" and "PDGFR" are describing two different molecules.

This page is for educational purposes only and is not medical advice; consult a licensed physician for any questions about medical conditions, medications or research participation. Nothing here describes a protocol, and the studies summarised below were conducted in cell cultures, animals or archived patient tissue rather than as instructions for people.

What the published literature reports

PDGFRα: development, fibroblasts and tissue remodelling

Developmental work has repeatedly placed PDGFRα upstream of mesenchymal cell behaviour. A mouse genetics study reported a stage-specific requirement for PDGFRα during embryonic development, with the consequences of receptor loss depending on when in gestation signalling was removed (PMID 28934221). A more recent paper reported that PDGFRα regulated fetal testis differentiation through an ERK–CREB signalling axis (PMID 41564132). In cultured human hepatic stellate cells — the mesenchymal cells implicated in liver scarring — researchers reported that PDGFRα contributed to proliferation and migration (PMID 28734947).

In the heart, an experimental study reported that PDGFRα was essential for cardiac fibroblast survival (PMID 31125253). Musculoskeletal work reported that postnatal tendon growth and remodelling required PDGFR signalling (PMID 29341790). A nanomedicine study took the targeting approach, reporting that a PDGFRα-directed, cell membrane-camouflaged nanotherapy disrupted fibrosis–inflammation coupling in a model of intervertebral disc degeneration (PMID 42426566).

PDGFRβ: pericytes, vessels and tumour behaviour

PDGFRβ appears most often in vascular and oncology contexts. A biochemical study reported that PDGFRβ activated the kinase Abl2 through direct binding and phosphorylation, describing a specific downstream connection rather than a clinical outcome (PMID 34144039). In the eye, researchers reported that targeting PDGFRβ-positive scaffold formation inhibited choroidal neovascularisation in an experimental model (PMID 27338108). A preprint reported that mutation of PDGFRβ caused and exacerbated the severity of brain arteriovenous malformation by enhancing angiogenesis; because that report was posted as a preprint, it had not completed journal peer review at the time of posting (PMID 41001557).

On the tumour side, an oncology study reported that PDGFRβ gene expression related to recurrence in colorectal cancer, an association observed in patient samples rather than an intervention result (PMID 29498405).

Representative findings at a glance

Safety and Adverse Events: What Studies Report

The verified literature summarised on this page consists of cell-culture experiments, animal genetics, tissue-expression surveys and one targeted nanotherapy model; these reports characterised receptor biology and did not establish human safety profiles for any PDGFR-directed product. No human dosing regimen, tolerability outcome or adverse-event rate is described in the studies cited here, so none is stated. The observation that PDGFRα loss compromised cardiac fibroblast survival (PMID 31125253) and that postnatal tendon growth required PDGFR signalling (PMID 29341790) illustrates why researchers treat the pathway as one with normal physiological roles as well as disease-associated ones — interference in one tissue does not occur in isolation.

Common points of confusion

1. PDGFR is not a peptide therapeutic. It is an endogenous receptor protein encoded by the PDGFRA and PDGFRB genes.
2. The two isoforms are not interchangeable. Studies of PDGFRα in fibroblasts and progenitors (PMID 29239330) address different biology from PDGFRβ work on pericytes and vessels (PMID 27338108).
3. Marker studies are descriptive. Reporting that CD117 and PDGFRα were expressed in alopecia areata tissue (PMID 32461384) describes an association, not a mechanism or a treatment.
4. Model results are not human results. Findings in rodents, cultured cells or preprints — including the brain arteriovenous malformation report (PMID 41001557) — require independent confirmation before conclusions are drawn about people.

References

• Platelet-Derived Growth Factor Receptor α Contributes to Human Hepatic Stellate Cell Proliferation and Migration (The American Journal of Pathology, 2017)
• Platelet-derived growth factor receptor beta activates Abl2 via direct binding and phosphorylation (Journal of Biological Chemistry, 2021)
• Platelet-derived growth factor receptor alpha regulates fetal testis differentiation via an ERK-CREB axis (PNAS, 2026)
• Postnatal tendon growth and remodeling require platelet-derived growth factor receptor signaling (American Journal of Physiology. Cell Physiology, 2018)
• Platelet-derived growth factor receptor-β gene expression relates to recurrence in colorectal cancer (Oncology Reports, 2018)
• Mutation of platelet-derived growth factor receptor β causes and exacerbates the severity of brain arteriovenous malformation through enhancing angiogenesis (Research Square, 2025)
• Expression of CD117 and platelet-derived growth factor receptor α in patients with alopecia areata (Indian Journal of Dermatology, Venereology and Leprology, 2020)
• Stage specific requirement of platelet-derived growth factor receptor-α in embryonic development (PLoS One, 2017)
• Expression of NG2 and platelet-derived growth factor receptor alpha in the developing neonatal rat brain (Neural Regeneration Research, 2017)
• Platelet-derived growth factor receptor-α is essential for cardiac fibroblast survival (American Journal of Physiology. Heart and Circulatory Physiology, 2019)
• Platelet-Derived Growth Factor Receptor α-Targeted Cell Membrane-Camouflaged Nanotherapy Disrupts Fibrosis-Inflammation Coupling in Intervertebral Disc Degeneration (ACS Nano, 2026)
• Targeting Platelet-Derived Growth Factor Receptor β(+) Scaffold Formation Inhibits Choroidal Neovascularization (The American Journal of Pathology, 2016)